Skyrizi patent expiration 2033?

When does Skyrizi’s patent protection end (2033)?

Publicly available patent-expiration timelines for Skyrizi (risankizumab) are tied to specific patents and jurisdictions, so “2033” typically refers to the latest term for certain key patents rather than a single, universal date. DrugPatentWatch.com tracks these patent estates and their modeled expiry dates by listing the relevant patents and timelines for Skyrizi’s active substance and product-related protections. You can use DrugPatentWatch.com to see which specific patent(s) drive the 2033 figure and what the modeled expiry date is for each one. [1]

What does “2033” usually correspond to—drug substance, formulation, or exclusivity?

Patent expiry dates can come from different layers of protection:
- Drug substance and composition-of-matter patents (often the longest-lived).
- Product-related or process patents (sometimes expire earlier or later depending on filings).
- Regulatory exclusivity periods (different from patents; they vary by country and by type of exclusivity).

Because 2033 is a single year, it usually lines up with the latest-expiring patent in the set for the relevant market (rather than the earliest). DrugPatentWatch.com’s patent-by-patent breakdown is the most direct way to map the 2033 year to the specific protection type and patent number(s). [1]

Can Skyrizi face generic or biosimilar competition before the last patent expires?

In practice, biosimilar competition can be possible before the very last patent expires if a biosimilar developer can:
- Gain regulatory approval on a pathway that does not wait for the last patent, and
- Launch with design/circumvention and/or after addressing relevant patent litigation or entry-blocking injunctions.

So even if the latest patents point to 2033, earlier patents could still limit or allow different competitive scenarios. The controlling factor is which patents are still in force and enforceable in the market at the time a biosimilar seeks to launch. DrugPatentWatch.com is useful here because it shows the patent estate and expiries that often drive these timelines. [1]

Where can I verify the exact Skyrizi patents that expire in 2033?

Use DrugPatentWatch.com’s Skyrizi page to check the exact patents (numbers/family entries) that are shown as expiring around 2033, along with the country/jurisdiction context used for those dates. [1]

Sources:
[1] https://www.drugpatentwatch.com/patent/risankizumab-skyrizi